RESEARCH BRIEF

Levamisole in Frequently-relapsing and Steroid-dependent Nephrotic Syndrome

EVANGELINE MARY KIRUBA SAMUEL, SRIRAM KRISHNAMURTHY, SINGANAMALLA BHANUDEEP AND SRAVANI MUSKE

From the Department of Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India.

Correspondence to: Dr Sriram Krishnamurthy, Additional Professor, Department of Pediatrics, JIPMER, Pondicherry 605 006, India. drsriramk@yahoo.com

PII: S097475591600077

ABSTRACT

Objectives: To evaluate the efficacy of levamisole in children with frequently relapsing nephrotic syndrome (FRNS) and steroid dependent nephrotic syndrome (SDNS) when administered on an alternate day ('initial therapy' in all cases) or daily basis ('rescue therapy' in whom alternate day therapy failed).

Methods: The records of 95 children (age 1-18y) with FRNS and SDNS, who were treated at the Pediatric nephrology clinic, and received levamisole therapy (maximum 2 years duration, between 2010-2013) with a follow-up period of minimum1 year, were included.

Results: Among the 95 cases with FRNS (*n*=62) and SDNS (*n*=33) studied, alternate day levamisole therapy was efficacious in 73.7% (*n*=70). The overall efficacy of levamisole therapy was 88.4% (*n*=84). Levamisole therapy decreased the mean (SD) number of relapses from 4.22 (0.46)/year to 1.35 (0.36)/year (*P*<0.01); and cumulative median (IQR) prednisolone dosage from 4200 (3200–4300) mg/m^2 to 1100 (IQR 500–2900) mg/m^2 (*P*<0.001). Daily levamisole therapy as 'rescue therapy' was effective in 56% (*n*=14) of children who had demonstrated alternate day levamisole failure (*n*=25). On a one-year follow up of the cases in whom alternate day or daily levamisole therapy was efficacious during therapy (median 24 months) (*n*=84), a frequently relapsing or steroid dependent course continued to persist in 48.8% (*n*=41), necessitating oral cyclophosphamide (*n*= 22) or mycophenolate mofetil (*n*=19).

Conclusions: Daily levamisole therapy was useful in 56% of children who demonstrated failure while on alternate day levamisole therapy, and could be a useful therapeutic option in FRNS and SDNS.

Keywords: *Corticosteroids, Immunomodulators, Proteinuria, Outcome, Treatment.*

INTRODUCTION

Nephrotic syndrome is a common renal disorder of childhood characterized by recurrent relapses. Of all the children who experience relapses, approximately 50% will develop frequently-relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), placing them at risk for steroid toxicity [1]. Levamisole is a common immunosuppressive drug used as a first line steroid sparing agent in the management of FRNS and SDNS [2-5]. There is are only few published studies regarding usage of levamisole, in FRNS and SDNS from India, [2,5]. Most studies and guidelines refer to alternate day levamisole therapy [1,3,5,6]. There is limited information regarding the usage of daily levamisole [2,7]. We conducted this study with the primary objective of evaluating the efficacy of levamisole in SDNS and FRNS children. The secondary objectives were to compare the efficacy of levamisole between SDNS and FRNS children and evaluate its efficacy when administered on daily or alternate day schedules.

METHODS

This retrospective record-based study was conducted in May and June 2016 after obtaining approval from the Institute Ethics Committee. We retrieved data from the case records of patients who were initiated on levamisole therapy between 2010-2013, with the last follow-up being completed in March 2016. The records of children age (1-18y) with FRNS and SDNS, who attended the Pediatric nephrology clinic and received levamisole therapy with a follow-up period of 1 year were included. Infantile nephrotic syndrome, congenital nephrotic syndrome and secondary nephrotic syndrome (such as lupus nephritis, IgA nephropathy, etc) were excluded. Waiver of consent was obtained as anonymity of subjects was maintained.

Definitions for FRNS, SDNS, remission and relapse were as per the Indian Pediatric Nephrology Group guidelines [1]. Other definitions used in the study were adapted from the same reference [1]: *success of levamisole therapy*: less than 2 relapses over a 6-month period while on alternate or daily levamisole; and f*ailure of levamisole therapy*: two or more relapses over a 6-month period while on alternate or daily levamisole.

In children with FRNS and SDNS, following treatment of a relapse, prednisolone was gradually tapered to maintain the patient in remission on alternate day doses of 0.5-0.7 mg/kg, which was administered for 9-18 months. If the steroid threshold to maintain remission was more than 0.5-0.7 mg/kg prednisolone on alternate days, after induction of remission with prednisolone (2 mg/kg/day), levamisole was administered at a dose of 2-2.5 mg/kg on alternate days for 24 months [1,8]. Co-treatment with prednisolone at a dose of 1.5 mg/kg on alternate days was given for 4 weeks; its dose was gradually tapered at the rate of 0.25 mg/kg every 4 weeks. If there was failure of alternate day levamisole therapy, daily doses of levamisole 2-2.5 mg/kg were administered along with alternate day prednisolone [6]. Total leukocyte count was performed 6-monthly while on levamisole therapy. If there was failure of daily levamisole therapy, oral cyclophosphamide or mycophenolate mofetil were used.

The cumulative doses of prednisolone and the number of relapses during therapy (and the year preceding the commencement of levamisole therapy) were recorded in a structured proforma. In children in whom levamisole therapy (alternate or daily) was a success, after completion of the 2-year course, the drug was discontinued. The number of relapses over the succeeding year was documented.

Statistical analysis: Data were expressed using proportions, median and inter-quartile ranges as well as means and SD wherever appropriate; and compared using student 't' or Mann Whitney U test respectively. Proportions were compared using $\chi 2$test or Fisher exact test. ANOVA or Kruskal Wallis test were used where appropriate. Data was evaluated using SPSS version 20.

RESULTS

A total of 95 children were included. The clinical characteristics of these children are shown in ***Table I***. In both SDNS and FRNS children taken together, levamisole (alternate day or daily therapy) was effective in 84 (88.4%) children. Children with FRNS showed a better response to levamisole as

compared to SDNS (82% *vs* 58%, *P*=0.01). Daily levamisole therapy was successful in 14/25 (56%) children who failed on alternate day levamisole. No adverse effects such as leukopenia, hepatotoxicity, rash or flu-like illnesses were recorded. The mean (SD) threshold of prednisolone for starting levamisole in FRNS was 0.92 (0.14) mg/kg while the corresponding threshold for SDNS was 0.88 (0.17) mg/kg (*P*=0.22).

The relapse rates as well as the cumulative dose of steroids decreased significantly during levamisole therapy (*P*<0.01) (***Table* II**). Overall, there was an increase in relapse rate to a mean of 2.57relapses/year after completion of therapy. In 41/84 (48.8%) of children in whom levamisole therapy was efficacious, the effect of levamisole was not sustained after stopping the drug, and a frequently-relapsing or steroid-dependent course continued to persist necessitating alternative immunosuppressants [oral cyclophosphamide (*n*= 22); mycophenolate mofetil (*n*=19)].

DISCUSSION

Beneficial effects of levamisole in terms of reduction in relapse rates and significantly reduced cumulative dosage of steroids have been documented in published literature [6-14]. A meta-analysis has also documented the efficacy of levamisole [4]. We too found that alternate day levamisole along with initial low dose steroid therapy can be effective in children with FRNS/SDNS (with a better efficacy in FRNS). However, the observation that almost half of the children continue to have a frequently relapsing or steroid dependent course after discontinuation of the drug, implies lack of a remnant effect of the drug. Our study also demonstrated that daily levamisole is a feasible and efficacious option in 56% of children who failed alternate day therapy. This is an important observation because current guidelines [1] recommend only alternate day levamisole and advise usage of other alternate immunosuppressants such as oral cyclophosphamide or mycophenolate mofetil in case of alternate-day levamisole failure.

The rationale for usage of daily levamisole is based on the fact that the half-life of levamisole is 5.2 hours [7,11]. Ekambaram, *et al*. [2] reported that daily levamisole was effective in 77.3% of 95 children. Fu, *et al*. [7] in a comparative study between daily and alternate day levamisole usage in children with FRNS and SDNS, reported that daily levamisole usage can be considered when response to alternate day usage is unsatisfactory. La Manna, *et al*. [11] studied the effect of levamisole on 13 FRNS and/or SDNS children. These children were treated with 2.5 mg/kg levamisole twice a week (Cycle A) for 2-16 months (mean 5.8 months). Following failure of the regime, 8 children were given the same dose of levamisole on a daily basis. A clinical improvement was observed in 6 children; 4 with cycle A and 2 with cycle B. The authors noted minimal side effects (*e.g.*, transient neutropenia) in both drug regimes. We did not observe any side effects attributable to levamisole, similar to the observations of Ekambaram, *et al*. [2]

The study adds valuable information regarding the efficacy of alternate day or daily levamisole therapy. The retrospective nature of the study, however, makes it more susceptible to 'selection bias'. Randomized controlled trials evaluating daily levamisole in comparison to other therapeutic options in children who fail alternate day therapy with levamisole are needed to further validate these results. Nevertheless, based on the observations of our study, it may be prudent to recommend a trial of daily levamisole in children who demonstrate alternate day levamisole therapy failure before switching over to more potentially toxic therapeutic options.

Contributors: EMKS collected the data, was involved in protocol preparations and drafted the manuscript. SK managed the patients, conceptualized the study, reviewed the literature and critically reviewed the manuscript. SB and SM were involved in the management of the patients, performed the statistical analysis, and assisted in drafting the manuscript. All authors contributed to writing the paper and approved the final version of the manuscript.
Funding: None; *Competing interest***:** None stated.

WHAT THIS STUDY ADDS?

- Daily levamisole therapy is a useful therapeutic option in more than half of children with FRNS or SDNS in whom failure of alternate day levamisole therapy was documented.
- About half of children with FRNS and SDNS who complete the course of levamisole therapy continue to have a frequently-relapsing or steroid-dependent course after discontinuation of the drug.

REFERENCES

1. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, *et al*. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2008;45:203-14.
2. Ekambaram S, Mahalingam V, Nageswaran P, Udani A, Geminiganesan S, Priyadarshini S. Efficacy of levamisole in children with frequently relapsing and steroid-dependent nephrotic syndrome. Indian Pediatr. 2014;51:371-3.
3. Sinha A, Hari P, Sharma PK, Gulati A, Kalaivani M, Mantan M, *et al*. Disease course in steroid sensitive nephrotic syndrome. Indian Pediatr. 2012;49:881-7.
4. Davin JC, Merkus MP. Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Pediatr Nephrol. 2005;20:10-4.
5. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol. 1997;11:415-7.
6. Hafeez F, Ahmed TM, Samina U. Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. J Coll Physicians Surg Pak. 2006;16:35-7.
7. Fu LS, Shien CY, Chi CS. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: Comparison of daily and every-other day usage . Nephron Clin Pract. 2004;97:c137–c41.
8. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2013;CD002290.
9. Madani A, Isfahani ST, Rahimzadeh N, Fereshtehnejad SM, Hoseini R, Moghtaderi M, *et al*. Effect of levamisole in steroid-dependent nephrotic syndrome. Iran J Kidney Dis. 2010;4:292-96.
10. Al-Saran K, Mirza K, Al-Ghanam G, Abdelkarim M. Experience with levamisole in frequently relapsing, steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2006;21:201-5.
11. La Manna A, Polito C, Del Gado R, Foglia AC. Levamisole in children's idiopathic nephrotic syndrome. Child Nephrol Urol. 1988;9:200-2.
12. Sumegi V, Haszon I, Ivanyi B, Bereczki C, Papp F, Turi S. Long-term effects of levamisole treatment in childhood nephrotic syndrome. Pediatr Nephrol. 2006;19:1354-60.
13. Dayal U, Dayal AK, Shastry JC, Raghupathy P. Use of levamisole in maintaining remission in steroid-sensitive nephrotic syndrome in children. Nephron. 1994;66:408-12.
14. Meregalli P, Bianchetti MG, Imoberdorf G, Lutschg J, Reymond D, Oetliker OH. Levamisole in children with frequently recurring idiopathic nephrotic syndrome. Schweiz Med Wochenschr. 1994;124:801-5.

TABLE I CLINICAL CHARACTERISTICS OF CHILDREN ENROLLED IN THE STUDY WITH NEPHROTIC SYNDROME TREATED WITH LEVAMISOLE

	Frequently Relapsing Nephrotic syndrome *[n= 62]*	*Steroid Dependent Nephrotic Syndrome* *[n= 33]*	*P value*
Age at enrolment	8 (61,2.5)	9.5 (5.5,14)	0.301
Age at onset	2.5 (1.9,4)	2 (1.8,4)	0.398
Age at initiation of levamisole	5 (3,8)	6 (3,8)	0.654
Males [*n* (%)]	37 (59.7)	18 (54.6)	<0.001
Duration of Levamisole therapy (mo)			
In children in whom it was efficacious (months)	24 (12.5,24)	24 (7.8,24)	0.166
In children in whom it was not efficacious (months)	7 (5.25,8)	6 (6,9)	0.010
Efficacy of alternate day levamisole therapy (%)	82	58	0.010
Overall efficacy of levamisole (daily and alternate therapy) (%)	93.5	79	0.035

Value in median (IQR) unless specified otherwise.

TABLE II RELAPSE RATES AND CUMULATIVE DOSAGE OF PREDNISOLONE BEFORE, DURING AND AFTER LEVAMISOLE THERAPY IN THE STUDY SUBJECTS

	1 year before therapy	***During therapy***	***1 year after discontinuation***
FRNS (n=62)			
No. of relapses per year	4.21 (0.45)	1.11 (1.18)	2.55 (1.1)*
Cumulative dose of prednisolone received (mg/m^2)	4200 (3125, 5200)	1000 (400, 1400)	2500 (1250, 3900)*
SDNS (n=33)			
No. of relapses per year	4.24 (0.56)	1.79 (1.58)	4.22 (0.46)#
Cumulative dose of prednisolone received (mg/m^2)	4200 (3500, 5600)	1300 (600, 4250)	3200 (2350, 4500)#
Overall (n=95)			
No. of relapses per year	4.22 (0.46)	1.35 (0.36)	2.57 (1.06)$
Cumulative dose of prednisolone received (mg/m^2)	4200 (3200, 4300)	1100 (500, 2900)	2800 (1375, 4200)$

P value <0.01 between the groups (within FRNS, SDNS and the overall subjects)
FRNS- Frequently relapsing Nephrotic Syndrome; SDNS-Steroid Dependent Nephrotic Syndrome
The data for the number of relapses is expressed as mean (standard deviation) while the data for the cumulative dose of prednisolone received is expressed as median (IQR).
**Calculated from amongst 51 children in whom the drug was efficacious*
 # Calculated from amongst 19 children in whom the drug was efficacious
$ Calculated from amongst 70 children in whom the drug was efficacious